ELI LILLY AND COMPANY

(LLY)
  Report
Real-time Estimate Cboe BZX  -  05/17 02:54:32 pm EDT
299.61 USD   +0.08%
05/16Lilly to Participate in UBS Global Healthcare Conference 2022
PR
05/16Eli Lilly Says FDA Approves Mounjaro Injection to Control Diabetes; Shares Rise
MT
05/13FDA Approves Lilly's Mounjaro (Tirzepatide) Injection, the First and Only GIP and GLP-1 Receptor Agonist for the Treatment of Adults with Type 2 Diabetes
CI
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Wells Fargo Adjusts Eli Lilly and Co.'s Price Target to $280 from $270, Keeps Equalweight Rating

01/04/2022 | 12:49pm EDT


ę MT Newswires 2022
All news about ELI LILLY AND COMPANY
05/16Lilly to Participate in UBS Global Healthcare Conference 2022
PR
05/16Eli Lilly Says FDA Approves Mounjaro Injection to Control Diabetes; Shares Rise
MT
05/13FDA Approves Lilly's Mounjaro (Tirzepatide) Injection, the First and Only GIP and GLP-1..
CI
05/13FDA Approves Eli Lilly's Novel, Dual-Targeted Treatment for Type 2 Diabetes
MT
05/13Berenberg Bank Adjusts Eli Lilly's Price Target to $345 From $305, Maintains Buy Rating
MT
05/13ELI LILLY AND COMPANY : Ex-dividend day for
FA
05/11Eli Lilly and Incyte Say Olumiant, Their COVID-19 Treatment for Hospitalized Adults, Ap..
MT
05/11FDA Approves Lilly, Incyte Drug Olumiant for Certain Hospitalized Covid Patients
DJ
05/11Artax Biopharma, Inc. announced that it has received $26 million in funding from Advent..
CI
05/10TRANSCRIPT : Eli Lilly and Company Presents at Bank of America 2022 Healthcare Conference,..
CI
More news
Analyst Recommendations on ELI LILLY AND COMPANY
More recommendations
Financials (USD)
Sales 2022 29 036 M - -
Net income 2022 6 997 M - -
Net Debt 2022 9 221 M - -
P/E ratio 2022 39,5x
Yield 2022 1,26%
Capitalization 269 B 269 B -
EV / Sales 2022 9,60x
EV / Sales 2023 9,09x
Nbr of Employees 35 000
Free-Float 99,8%
Chart ELI LILLY AND COMPANY
Duration : Period :
Eli Lilly and Company Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ELI LILLY AND COMPANY
Short TermMid-TermLong Term
TrendsNeutralBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 24
Last Close Price 299,38 $
Average target price 313,14 $
Spread / Average Target 4,59%
EPS Revisions
Managers and Directors
David A. Ricks Chairman, President & Chief Executive Officer
Anat Ashkenazi Chief Financial Officer & Senior Vice President
Daniel M. Skovronsky Chief Scientific Officer & Senior Vice President
Diogo Rau Senior VP, Chief Information & Digital Officer
Alonzo Weems Senior VP, Chief Ethics & Compliance Officer
Sector and Competitors
1st jan.Capi. (M$)
ELI LILLY AND COMPANY8.38%269 490
JOHNSON & JOHNSON4.10%468 600
PFIZER, INC.-14.19%284 304
ABBVIE INC.14.82%274 733
ROCHE HOLDING AG-14.96%260 807
MERCK & CO., INC.20.46%233 459